Quantitative evaluation of hard exudates in diabetic macular edema after short-term intravitreal triamcinolone, dexamethasone implant or bevacizumab injections
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Shin, Yong Un | - |
dc.contributor.author | Hong, Eun Hee | - |
dc.contributor.author | Lim, Han Woong | - |
dc.contributor.author | Kang, Min Ho | - |
dc.contributor.author | Seong, Mincheol | - |
dc.contributor.author | Cho, Heeyoon | - |
dc.date.accessioned | 2022-07-13T11:26:45Z | - |
dc.date.available | 2022-07-13T11:26:45Z | - |
dc.date.created | 2021-05-11 | - |
dc.date.issued | 2017-10 | - |
dc.identifier.issn | 1471-2415 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/151560 | - |
dc.description.abstract | Background To quantitatively compare short-term hard exudates (HEs) alteration in patients with diabetic macular edema (DME) after intravitreal triamcinolone, dexamethasone implant or bevacizumab injections. Methods This retrospective study enrolled DME eyes with HEs that underwent a single-dose intravitreal injection of triamcinolone (25 eyes), dexamethasone implant (20 eyes), or three monthly injections of bevacizumab (25 eyes) and completed at least three months of follow-up. All patients were examined before and after 1, 2 and 3 months of injections. Using color fundus photographs, the amount of HEs was quantified by two masked graders. The difference in HEs area between baseline and each follow-up visit was compared among the three groups. Results After three months, HEs area was reduced to 52.9 ± 4.21% (P < 0.001) in the triamcinolone group, 63.6 ± 6.08% (P = 0.002) in the dexamethasone implant group, and 85.2 ± 5.07% (P = 0.198) in the bevacizumab group. A significant reduction in HEs appeared at one month in the triamcinolone group (53.5 ± 4.91%, P < 0.001) and at two months in the dexamethasone implant group (70.1 ± 5.21%, P = 0.039). Conclusions Our study suggests intravitreal steroids (triamcinolone, dexamethasone implants) significantly reduce HEs in DME patients on short-term follow-up, whereas intravitreal bevacizumab does not. Therefore, intravitreal steroids may be useful in DME with HEs in the fovea. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | BMC | - |
dc.title | Quantitative evaluation of hard exudates in diabetic macular edema after short-term intravitreal triamcinolone, dexamethasone implant or bevacizumab injections | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Shin, Yong Un | - |
dc.contributor.affiliatedAuthor | Lim, Han Woong | - |
dc.contributor.affiliatedAuthor | Kang, Min Ho | - |
dc.contributor.affiliatedAuthor | Seong, Mincheol | - |
dc.contributor.affiliatedAuthor | Cho, Heeyoon | - |
dc.identifier.doi | 10.1186/s12886-017-0578-0 | - |
dc.identifier.scopusid | 2-s2.0-85030329852 | - |
dc.identifier.wosid | 000412205300003 | - |
dc.identifier.bibliographicCitation | BMC OPHTHALMOLOGY, v.17, no.1, pp.1 - 9 | - |
dc.relation.isPartOf | BMC OPHTHALMOLOGY | - |
dc.citation.title | BMC OPHTHALMOLOGY | - |
dc.citation.volume | 17 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 1 | - |
dc.citation.endPage | 9 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Ophthalmology | - |
dc.relation.journalWebOfScienceCategory | Ophthalmology | - |
dc.subject.keywordPlus | INTRAOCULAR-PRESSURE | - |
dc.subject.keywordPlus | FUNDUS IMAGES | - |
dc.subject.keywordPlus | ACETONIDE | - |
dc.subject.keywordPlus | RETINOPATHY | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordPlus | REDUCTION | - |
dc.subject.keywordAuthor | Bevacizumab | - |
dc.subject.keywordAuthor | Dexamethasone implant | - |
dc.subject.keywordAuthor | Diabetic macular edema | - |
dc.subject.keywordAuthor | Hard exudate | - |
dc.subject.keywordAuthor | Triamcinolone | - |
dc.identifier.url | https://bmcophthalmol.biomedcentral.com/articles/10.1186/s12886-017-0578-0 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.